An Open-Label, Multicenter, Non-Randomized Phase 2 Study Of Pf-06863135 Monotherapy In Participants With Multiple Myeloma Who Are Refractory To At Least One Proteasome Inhibitor, One Immunomodulatory Drug And One Anti-Cd38 Antibody